juliana tatelbaum is in london with more. good morning, juliana. >> reporter: frank, good morning.t suisse shares have had a volatile start to trade opening higher before sinking in the red. now they are bouncing above the flat line. this as losses related to archegos could amount to $4.7 billion. in a major overhaul, they axed the ceo and brian chin in the wake of the scandal. credit suisse has suspended its share buyback program and cut dividends and scrapped executive bonuses. the question for investors if this is enough to draw the line in the sand after the issues that credit suisse suffered. frank. >> juliana, this is a string of woes for the bank. can you put this in perspective? >> reporter: absolutely, frank credit suisse hit by a string of issues back in 2016, the bank agreed to pay $5.3 billion to the department of justice to resolve a case in mis-selling of mortgage securities. the scandals is the hiring of the private investigation team to monitor a former executive who moved to ubs the fallout of that episode would cost the then ceo his job. now credit suisse acted as

juliana tatelbaum is standing by in london with more on the developments good morning, juliana. >> reporterg day for the astrazeneca oxford vaccine the uk and the eu medical rem regulators held press conferences where they delivered conclusions after the possible links with astrazeneca and a rare number of blood clots here is what they found. starting in europe, european medicine agency concluded there is a possible link between the vaccine and the very rare cases of blood clots 86 cases reported. 18 were fatal. out of 25 million people who received the vaccine because they were not able to identify or confirm risk factors, ema stopped short of restricting use of the vaccine it was slightly different in the uk let's tell you what we heard yesterday. similar messaging here the regulator said there is mounting evidence of a link between the vaccine and the cases of rare blood clots. they say the benefits continue to outweigh the risks for the vast majority of people. those under the age of 30 should seek alternative vaccine when one is available this is not due to specific safety concerns, bu